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Background: A single-institutional prospective study of optimal hypofractionated conformal radiotherapy for large
brain metastases with high risk factors was performed based on the risk prediction of radiation-related complications.
Methods: Eighty-eight patients with large brain metastases ≥10 cm3 in critical areas treated from January 2010 to
February 2014 using the CyberKnife were evaluated. The optimal dose and number of fractions were determined
based on the surrounding brain volume circumscribed with a single dose equivalent (SDE) of 14 Gy (V14) to be less
than 7 cm3 for individual lesions. Univariate and multivariate analyses were conducted.
Results: As a result of optimal treatment, 92 tumors ranging from 10 to 74.6 cm3 (median, 16.2 cm3) in volume
were treated with a median prescribed isodose of 57% and a median fraction number of five. In order to
compare the results according to the tumor volume, the tumors were divided into the following three groups:
1) 10–19.9 cm3, 2) 20–29.9 cm3 and 3) ≥30 cm3. The lesions were treated with a median prescribed isodose of
57%, 56% and 55%, respectively, and the median fraction number was five in all three groups. However, all
tumors ≥20 cm3 were treated with ≥ five fractions. The median SDE of the maximum dose in the three groups
was 47.2 Gy, 48.5 Gy and 46.5 Gy, respectively. Local tumor control was obtained in 90.2% of the patients, and
the median survival was nine months, with a median follow-up period of seven months (range, 3-41 months).
There were no significant differences in the survival rates among the three groups. Six tumors exhibited marginal
recurrence 7-36 months after treatment. Ten patients developed symptomatic brain edema or recurrence of
pre-existing edema, seven of whom required osmo-steroid therapy. No patients developed radiation necrosis
requiring surgical resection.
Conclusion: Our findings demonstrate that the administration of optimal hypofractionated conformal radiotherapy
based on the dose-volume prediction of complications (risk line for hypofractionation), as well as Kjellberg’s necrosis risk
line used in single-session radiosurgery, is effective and safe for large brain metastases or other lesions in critical areas.
Keywords: Large brain metastases, Hypofractionated conformal radiotherapy, Multi-session radiosurgery, Prediction of
complications, Radiation necrosis, Brain edema, Optimal dose and fraction, V14* Correspondence: chair.ino@instno-med.org
1Cyber Center, Kanto Neurosurgical Hospital, 1120 Dai, Kumagaya, Saitama
360-0804, Japan
2Neurosurgery and Radiation Oncology, Institute of Neural Organization,
1120 Dai, Kumagaya, Saitama 360-0804, Japan
Full list of author information is available at the end of the article
© 2014 Inoue et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Inoue et al. Radiation Oncology 2014, 9:231 Page 2 of 9
http://www.ro-journal.com/content/9/1/231Background
Surgical removal is the gold standard therapy and is essen-
tial for treating large brain metastases causing progressive
symptoms due to increased intracranial pressure, as the
symptoms improve immediately after surgery. However,
surgical removal carries a risk of causing neurological defi-
cits after dissecting critical areas, especially in cases of tu-
mors situated deep within the white matter. Surgery also
requires hospitalization for at least one week, with higher
medical expenses than that observed for radiosurgery in
this country. In addition, there are many patients with
general risks for surgery, as well as those who refuse surgi-
cal procedures, due to having primary malignancies and/
or a poor performance status.
Whole brain radiotherapy (WBRT) and chemotherapy
are not adequate to control large brain metastases, and
radiosurgery is an important therapeutic tool for treating
brain metastases in multiple clinical settings. Moreover,
radiosurgery is increasingly being used as a primary
treatment modality in an attempt to prevent distur-
bances in the neurocognitive function after WBRT [1].
However, single-session radiosurgery is also inadequate
for managing large brain metastases due to dose limita-
tions resulting from the need to prevent adverse effects
on the surrounding structures, such as the optic path-
way, internal capsule and brainstem [2].
Hypofractionated radiotherapy appears to be beneficial
in case of metastases not causing clinical signs of
impending cerebral herniation, and its use is supported
by the findings of previously published series employing
varying radiation dose and fractionation schedules [3-7].
However, the optimal dose and number of fractions have
yet to be established [8], and the exact incidence of ad-
verse effects on the surrounding brain is unclear in pa-
tients with tumors with high risk factors, such as a large
size or location in a critical area. Therefore, in order to
determine the optimal dose and fractionation schedule,
dose escalation following low-dose treatment is required.
We previously reported that the brain volume circum-
scribed with a single dose equivalent (SDE) of 14 Gy (V14)
is an indicator of radiation necrosis [9] and that the inci-
dence of radiation-related complications after hypofractio-
nated conformal radiotherapy is best predicted according
to the dose-volume relationship using the SDE of the
maximum dose and V14 [10]. In January 2010, we initi-
ated a prospective study of optimal hypofractionated
conformal radiotherapy based on risk prediction in
order to avoid radiation necrosis after hypofractiona-
tion treatment for large brain metastases in addition to
the Kjellberg’s necrosis risk line used in single-session
radiosurgery [11].
This report presents the results of our single-institution
prospective study of optimal hypofractionated conformal
radiotherapy performed in this institute as useful treatmentfor patients with large brain metastases in critical areas
and/or those with general risks for surgery.
Methods
All patients provided their written informed consent prior
to the procedure with institutional ethics committee ap-
proval. Ninety-seven patients with large brain metastases
measuring 10 cm3 in volume or more were treated with
optimal hypofractionated radiotherapy based on the dose-
volume prediction of complications in order to avoid radi-
ation necrosis and subsequently followed more than three
months at Kanto Neurosurgical Hospital between January
2010 and February 2014. An evaluation of the rates of local
tumor control, overall survival and complications was per-
formed as a prospective single-institutional analysis.
Definition of variables and end points
The treatment dose is expressed as the marginal dose
used in hypofractionated conformal radiotherapy. The
maximum dose was automatically obtained from the
marginal dose and the prescribed isodose delivered to
the lesion margin. A complication was defined as neuro-
logical impairment (either the development of a new
deficit or the significant deterioration of a preexisting or
recurrent deficit) with a change on either computerized
tomography scans or magnetic resonance imaging stud-
ies. Clinical follow-up was considered to have stopped at
the time of the most recent report from the patient and/
or a representative or the time of death.
Inclusion and exclusion criteria
Ninety-seven patients followed for more than three
months after treatment were found to be eligible for in-
clusion in this study. Nine patients (9.3%) were excluded
from the analysis due to a lack of available imaging find-
ings after treatment. All other patients (88) were in-
cluded in the analysis.
Patient characteristics
The median age of the patients was 64 years; 42 patients
(47.7%) were 65 years of age or older. The primary can-
cers were located in the lung, breast, gastrointestinal
tract, ovary, kidney, thyroid, larynx, uterus, or other re-
gions (liver, testis, etc.). The tumors (n =92) treated ac-
cording to the hypofractionation protocol were situated
in the frontal lobe (close to the optic pathway, Broca’s
area or motor cortex), parietal lobe (sensory cortex or
dominant angular cortex), temporal lobe (close to the
optic pathway or Wernicke’s area), occipital lobe (visual
cortex), thalamus, basal ganglia or cerebellum close to
the brainstem. The median Karnofsky Performance sta-
tus (KPS) score was 70, and 34 patients (38.6%) had a
KPS score of less than 70. The initial tumor volume was
measured using the MultiPlan (Accuray, Sunnyvale, CA)
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ume based on the findings of enhanced T1-weighted
magnetic resonance imaging (MRI). The median tumor
volume of 92 lesions was 16.2 cm3. Forty-nine tumors
(53.3%) were larger than 15 cm3 (more than 3 cm in
diameter). Thirteen tumors measured 30 cm3 or more
(4 cm in diameter) up to 74.6 cm3. Table 1 shows the
patient characteristics.
Prescribed marginal and SDE of the maximum dose
The maximum dose was calculated based on the mar-
ginal dose and prescribed isodose. For the purpose of
the dose-volume analysis, the maximum dose in three-
to ten-fraction treatment was converted to the SDE
using the equation reported by Park et al. and Eaton
et al. [8,12], as previously reported [10].
Optimal hypofractionated conformal radiotherapy
Hypofractionated conformal radiotherapy was adminis-
tered under CT and MRI guidance as previously reported
[9]. When setting a dose and fraction schedule as the first
plan, a marginal dose of 27–30 Gy in three fractions was
intended to use to treat tumors measuring 10–19.9 cm3.
A marginal dose of 31–35 Gy in five fractions and a mar-
ginal dose of 35–42 Gy in eight to 10 fractions were
intended to use to treat tumors measuring 20–29.9 cm3Table 1 Pretreatment characteristics of the 88 patients with l
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Metastases to other organs 50and tumors measuring 30 cm3 or more, respectively. The
isodose volume of the surrounding brain (excluding the
GTV) circumscribed with an SDE of 14 Gy (V14), as well
as the tumor volume, was measured using the MultiPlan
software program for the G4 system (Accuray, Sunnyvale,
CA) and recorded in each patient in order to obtain the
optimal dose and fractionation schedule. The SDE of
14 Gy used in three- to ten-fraction treatment was 23.1 to
38.4 Gy according to Timmerman’s values [13], as previ-
ously reported [10]. The V14 of each tumor was main-
tained at less than 7 cm3 in order to prevent radiation
necrosis for optimal treatment based on the dose-volume
prediction of complications [10]. If the V14 value was
more than 7 cm3 in the first dose-plan, it was lowered to
less than 7 cm3 using a decreased marginal isodose or
dose or an increased number of fractions in the revised or
re-revised dose-plan, maintaining an effective marginal
dose (SDE: 18–20 Gy) on the target.
Follow-up evaluations and complications
Changes in the patients’ neurological symptoms, such as
paresis, sensory disturbances, aphasia or visual distur-
bances, were examined after treatment. Serial imaging
studies (MRI or CT) were requested six weeks after
treatment and every two to three months thereafter.
Symptomatic brain edema was identified in associationarge brain metastases in critical areas
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the concomitant perifocal regions after treatment. The
tumor response was divided into three groups, reduced
(a decrease in the tumor volume of >15%), stable (a change
in the tumor volume within ±15%) or enlarged (an increase
in the tumor volume of >15%), in order to compare the re-
sponse with that observed in former reports of large brain
metastases [9,10]. The incidence of complications was ex-
amined in relation to the V14 of the surrounding brain.
Statistical analysis
Univariate and multivariate analyses were conducted
using logistic regression and Cox hazard models. Differ-
ences between the groups were evaluated using Student’s
t-test. Overall survival was estimated according to the
Kaplan-Meier method and examined for significance
using the log-rank and generalized Wilcoxon tests. All
analyses employed the conventional p < 0.05 level of
significance.
Results
Nineteen patients received osmo-steroid therapy during
hypofractionation treatment for symptoms of perifocal
edema and/or the further oral administration of steroids
depending on the presence of other symptoms at the
outpatient clinic.
Follow-up evaluations
No new neurological deficits from direct damage to the
optic pathway, brainstem or functional areas were noted,
although symptoms recurred or appeared in 10 patients
due to adverse effects (brain edema) on the surrounding
brain.
Treatment-related variables of optimal hypofractionation
The prescribed isodoses ranged from 50% to 70% (median,
57%) for the target. The SDE of the maximum dose
ranged from 36.8 to 61.9 Gy (median, 47.4 Gy) delivered
in three to 10 fractions (median, five). Twenty-one tumors
were treated with more than five fractions. The median
V14 value was 5.0 cm3 (Table 2). The results are shown
for each of the three groups divided according to the
tumor volume in Table 3. The prescribed isodose declined
according to the tumor volume, although no significant
differences were found among the three groups. Large tu-
mors measuring 20 cm3 or more were treated with five
fractions or more in order to maintain a V14 of less than
7 cm3. A large number of fractions (more than five) was
used, even in tumors measuring less than 20 cm3, in order
to decrease the V14 to less than 3 cm3 or 1 cm3 for tu-
mors in critical areas, such as the motor cortex, basal gan-
glia, thalamus or pyramidal tract (concerning normal
tissue dose constraints), or those associated with extensive
brain edema. There were no significant differences in theSDE of the maximum dose or V14 values among the three
groups.
Tumor response, local control and overall survival after
treatment
All 92 lesions in the 88 patients were subjected to se-
quential imaging studies from one to 37 months (me-
dian, seven months) after treatment. All but five of the
92 lesions (three enlarged and two stable) showed tumor
regression on follow-up images (Table 3, Figure 1). Six
lesions exhibited marginal recurrence and required add-
itional treatment. A second cycle of treatment was per-
formed at the recurrent areas only, excluding the central
areas treated with higher doses (Figure 1C). The local
tumor control rate was 90.2%, with a median survival of
nine months (Figure 2). There were no significant differ-
ences in the survival rates among the patients with tu-
mors measuring 10–19.9 cm3, 20–29.9 cm3 or ≥30 cm3
after treatment (log-rank test: p =0.50, generalized
Wilcoxon test for group 1&2 vs. 3: p =0.32) although the
rate of survival was lower in the patients with tumors
measuring ≥30 cm3 than in the other groups (Figure 3).
Tumor recurrence
Marginal regrowth of the treated lesions occurred in six
patients seven to 36 months after treatment; all tumors
were located in the cerebral hemisphere (Table 4). The
tumors were treated with a median prescribed isodose of
57% and median SDE of the maximum dose of 48.4 Gy.
Table 3 Results of optimal hypofractionation in the three groups divided according to the tumor volumes
Tumor volume (cm3) (median) 10–19.9 (13.4) 20–29.9 (23.8) 30–74.6 (37.5)
Median isodose (%) (range) 57 (50–70) 56 (51–64) 55 (51–64)
Median fraction Number (range) 5 (3–10) 5 (5–10) 5 (5–8)
Median SDE of the max. dose (Gy) (range) 47.2 (36.8-61.9) 48.5 (38.1-61.5) 46.5 (39.7-56.0)
Median V14 (cm3) 5.1 4.4 5.2
(range) (0.3-6.9) (0.7-6.1) (0.4-6.1)
Median KPS 70 70 65
(range) (50–100) (50–80) (50–90)
Tumor response
Reduced (87) 58 17 12
Stable (2) 0 1 1
Enlarged (3) 3 0 0
Marginal recurrences (6) 4/61 (6.6%) 2/18 (11.1%) 0/13 (0%)
Complications (10) (brain edema) 5/61 (8.2%) 4/18 (22.2%) 1/13 (7.7%)
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multivariate analyses. However, the difference in the
tumor volumes (10–19.9 cm3 vs 30–74.6 cm3) between
the groups was significant (p =0.02), whereas the differ-
ence in the tumor location (cerebrum vs. others) was
not (p =0.16). All tumors recurred more than six months
after treatment, and the difference between the groups
(followed for <6 months vs. ≥6 months) was found to be
significant (p =0.001).
Adverse effects (brain edema)
Six patients who experienced recurrent symptoms and
one patient who developed new symptoms due to exten-
sive brain edema required osmo-steroid therapy. The
symptoms and edema rapidly improved after the osmo-
steroid therapy. Each of these patients received further
oral administration of steroids at the outpatient clinic.
Two patients who displayed recurrent symptoms and
one patient who exhibited new symptoms due to perifo-
cal edema required the oral administration of steroids at
the outpatient clinic. These 10 patients showed both
clinical and radiological deterioration one to 16 months
after treatment. Two of these patients demonstrated
newly developed brain edema, while the remaining eight
patients presented with the extension of pre-existing
brain edema that had been present prior to treatment.
The median age of these patients was 69 years, which
was older than that of the total population (Table 5).
Each of these patients were treated with 5–10 fractions
(median, 6). The V14 of the patients with brain edema
ranged from 3.6 to 6.1 cm3. In the univariate analyses,
age and the number of fractions were found to be sig-
nificant factors for complications; however, only the
number of fractions was found to be significant in the
multivariate analyses. Differences between the groupswere significant for each of the following factors: age
(≥60, p = 0.02), number of fractions (≥5, p = 0.0006) and
duration of edema (<6 months, p = 0.001). In contrast,
the differences in tumor volume between the three
groups were not significant, nor were the differences in
the number of patients treated with or without osmo-
steroid therapy during hypofractionation treatment.Discussion
The prognosis of patients with brain metastases is re-
lated to the stage of the primary cancer, age and the KPS
score [14,15]. The worst survival is seen in patients with
a KPS of less than 70. In the present series, 38.6% of the
patients had a KPS of less than 70 and 65.9% of the pa-
tients were 60 years of age or older. Although 78 pa-
tients (88.6%) were in RTOG-RPA class 2 or 3, the
median survival of our patients was nine months. Fur-
thermore, no statistically significant differences were
found between the three groups of patients divided ac-
cording to the tumor volume, although the survival rate
and median KPS score were lowest in the largest group.
Optimal hypofractionated conformal radiotherapy helps
to increase the KPS, at least in patients with symptom-
atic lesions not directly affecting functional areas, and
contributes to improving the prognosis of patients with
large brain metastases, as previously reported [9].
Single-session radiosurgery is increasingly being used
to treat brain metastases and has the benefits of a short
treatment time, high tumor control rate and low risk of
complications. However, large metastases are not suit-
able for treatment with single-session radiosurgery, as
lower tumor control rates (85%) and higher complica-
tion rates (15%) than those for smaller metastases have
been reported [2,16].
Figure 1 Tumor regression after optimal hypofractionated conformal radiotherapy. A: Gd-enhanced T1-weighted MR images. Lung cancer
brain metastasis in a 73-year-old male. A large residual tumor (74.6 cm3) obtained after partial removal due to an impending brain hernia was
treated with a marginal dose of 27 Gy in five fractions at an isodose of 56% (left). A significant tumor response with no adverse imaging effects
was found four months after the administration of conformal radiotherapy (right). The patients’ left hemi-paresis disappeared, and the KPS improved
from 60 to 70. B: Contrast-enhanced CT scans (MR images not available for the pace maker implant). Lung cancer brain metastasis in a 52-year-old
female. A tumor in the thalamus (10.6 cm3) with perifocal edema was treated with a marginal dose of 31 Gy in five fractions at an isodose of 63% (left).
A tumor response was observed seven months after the administration of conformal radiotherapy (right). The patients’ left hemiparesis was
ameliorated, and the KPS improved 60 to 70 (walking with a stick 32 months after treatment). C: Gd-enhanced T1-weighted MR images. Breast
cancer brain metastasis in a 70-year-old female. A large tumor in the parietal lobe (23.5 cm3) with perifocal edema was treated with a marginal
dose of 35 Gy in eight fractions at an isodose of 57% (left). A tumor response was found two months after treatment, Gerstmann’s syndrome
disappeared, and the KPS improved 60 to 70. Marginal recurrence was noted 20 months after the first treatment, and the recurrent lesion
(1.7 cm3) was treated with a marginal dose of 20 Gy at an isodose of 69% in single-session radiosurgery (center). A tumor response with no
adverse imaging effects was found 34 months after the first treatment (right).
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yielded a tumor control rate of 90.2% in the patients
with large tumors. The median maximum dose (SDE) of
47.4 Gy at a median prescribed isodose of 57% in amedian of five fractions appeared to be effective for most
large brain metastases, in addition to a marginal dose of
20 Gy at the prescribed isodose of 50-60% for small tu-
mors in single fraction radiosurgery. However, more
Figure 2 Kaplan-Meier survival curves of the 88 patients with large brain metastases treated with optimal treatment.
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mors measuring more than 20 cm3 or tumors associated
with extensive brain edema in order to decrease the V14
values.
Consequently, tumor recurrence appeared in six pa-
tients more than six months after treatment, all of which
originated from marginal areas treated with the pre-
scribed isodose. Additional treatment was easily per-
formed in these patients, because the volume of the
recurrent tumors was not large, and the risk of radiation
necrosis after the second treatment was assessed to be
very low. As to risk factors for recurrence, a larger
tumor volume, lower prescribed isodose and lower SDE
of the maximum dose are potential candidates; however,
no factors were found to be significant in the univariate
or multivariate analyses in this study. The difference in
tumor volume (10–19.9 cm3 vs 30–74.6 cm3) between
the groups was significant; however, recurrence occurred
in only four of 61 patients with smaller tumors. Although
greater sample size is required for further statistical ana-
lyses, our findings indicate that optimal hypofractionatedFigure 3 Kaplan-Meier survival curves of the patients with large brain
measuring 10–19.9 cm3, group 2): patients with tumors measuring 20–29.9 cm
significant differences were found between the groups.conformal radiotherapy is effective for treating large le-
sions with a low rate of recurrence.
Brain edema developed in 10 patients, mostly within
six months. With respect to risk factors, age and the
number of fractions were found to be significant in this
series. Older patients’ brains with large metastases may
be sensitive to irradiation stress or possibly exhibit
greater vulnerability than the normal adult brain. More
than five fractions were used to treat large tumor meas-
uring more than 20 cm3, tumors associated with exten-
sive edema or tumors located in critical areas. Tumors
situated deep within the white matter have a tendency to
cause brain edema, and factors related to the onset of
edema may promote the development or re-appearance
of brain edema. In contrast to that observed for radi-
ation necrosis, most cases of brain edema developed sev-
eral months after treatment, and all were reversible and
recovered after either osmo-steroid therapy or oral ster-
oid treatment. Therefore, optimal hypofractionated con-
formal radiotherapy is a safe treatment for patients with
large metastases with high risk factors.metastases in the three groups. Group 1): patients with tumors
3, group 3): patients with tumors measuring ≥30 cm3. No statistically
Table 4 Characteristics of the six patients with recurrences after optimal hypofractionated conformal radiotherapy
Median (range) Univariate Multivariate
p value p value HR 95% CI
Age 68.5 (56–82) 0.17 0.20 1.09 0.95-1.25
Sex M: 3, F: 3 0.91 0.29 0.23 0.01-3.63
Tumor location Cerebrum (P: 2, F: 2, T: 1, O: 1) 0.85 0.75 1.13 0.53-2.39
Tumor volume (cm3) 18.0 (11.9-24.0) 0.69 0.69 1.04 0.85-1.29
Prescribed isodose (%) 57 (52–66) 0.97 0.73 0.93 0.63-1.37
Fraction number 5 (3–8) 0.89 0.73 0.82 0.27-2.49
SDE of the max. dose (Gy) 48.4 (36.8-54.3) 0.72 0.40 0.85 0.58-1.25
V14 (cm3) 4.9 (3.7-5.1) 0.78 0.90 1.07 0.35-3.32
HR: Hazard ratio, CI: Confidence interval, P: Parietal, F: Frontal, T: Temporal, O: Occipital.
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essential for providing optimal hypofractionation treat-
ment. We previously reported a method for predicting ra-
diation necrosis using a model that accounted for the SDE
of the maximum dose and V14 [10]. Long-term experi-
ence with single-session radiosurgery has also confirmed
the optimal treatment doses for individual pathologies in
the brain. For example, a marginal dose of 12 Gy or 20 Gy
is used to treat vestibular schwannoma or AVM, respect-
ively. The long-term results have been shown to be satis-
factory, with low rates of complications [17,18]. The
optimal dose and fraction number for hypofractionation
treatment for such pathologies may be determined by pre-
dicting the incidence of complications with respect to
avoiding adverse effects on the surrounding brain.
In this prospective study, our findings demonstrated a
rate of high tumor control and a low rate of complica-
tions in the treatment of large brain metastases with
high risk factors. No patients with radiation necrosis re-
quired surgical resection during the median follow-up of
seven to 41 months. Therefore, the administration of de-
fined optimal hypofractionation treatment based on the
dose-volume prediction of complications is effective andTable 5 Characteristics of the 10 patients with adverse effect
Median (range) U
p
Age 69 (59–84) 0
Sex M: 7, F: 3 0
Tumor location Cerebrum: 9, cerebellum: 1 0
Tumor volume (cm3) 20.5 (10.0-32.9) 0
Prescribed isodose (%) 57 (51–65) 0
Fraction number 6 (5–10) 0
SDE of the max. dose (Gy) 48.0 (40.5-55.3) 0
V14 (cm3) 4.7 (3.6-6.1) 0
CH: Cox hazard, HR: Hazard ratio, CI: Confidence interval, *: Significant.safe for the treatment of large lesions. However, the V14
may need to be further reduced to less than 3 cm3 when
treating tumors situated deep within the white matter
and/or exhibiting extensive perifocal edema, as the rate
of recurrence of pre-existing edema was not low in the
patients with a V14 of 3 cm3 or more after treatment in
this series. Conformal radiotherapy with a prescribed
isodose of 50% to 60% has the benefits of decreasing the
V14 value due to a sharp fall-off in the dose distribution,
as noted with single-session radiosurgery. Optimal treat-
ment using a large fraction number also has the benefits
of decreasing the V14 value and helps to avoid radiation
necrosis, as demonstrated in this prospective study.Conclusion
This prospective study of optimal dose and fractionation
treatment for large brain metastases with high risk factors
showed satisfactory results for local tumor control and sur-
vival, with limited complications. Conducting dose-volume
prediction of complications using the V14 is beneficial for
preventing irreversible complications in the treatment of
large brain metastases or other lesions in the brain.s after optimal hypofractionated conformal radiotherapy
nivariate Multivariate
value (CH model) p value HR 95% CI
.04* (0.03*) 0.14 1.05 0.99-1.11
.15 0.08 0.26 0.06-1.18
.63 0.67 0.91 0.59-1.90
.86 0.34 0.96 0.88-1.05
.77 0.88 0.98 0.79-1.22
.007* (0.004*) 0.007* 2.04 1.21-3.43
.50 0.51 0.94 0.77-1.13
.92 0.88 0.96 0.57-1.61
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